124 related articles for article (PubMed ID: 26011703)
41. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3.
Li WC; Ye SL; Sun RX; Liu YK; Tang ZY; Kim Y; Karras JG; Zhang H
Clin Cancer Res; 2006 Dec; 12(23):7140-8. PubMed ID: 17145839
[TBL] [Abstract][Full Text] [Related]
42. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ
Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673
[TBL] [Abstract][Full Text] [Related]
43. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
44. MLN-8237: A dual inhibitor of aurora A and B in soft tissue sarcomas.
Nair JS; Schwartz GK
Oncotarget; 2016 Mar; 7(11):12893-903. PubMed ID: 26887042
[TBL] [Abstract][Full Text] [Related]
45. (-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis.
Shirakami Y; Shimizu M; Adachi S; Sakai H; Nakagawa T; Yasuda Y; Tsurumi H; Hara Y; Moriwaki H
Cancer Sci; 2009 Oct; 100(10):1957-62. PubMed ID: 19558547
[TBL] [Abstract][Full Text] [Related]
46. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer.
Younes MN; Yazici YD; Kim S; Jasser SA; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3425-34. PubMed ID: 16740767
[TBL] [Abstract][Full Text] [Related]
47. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
48. The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
Jiang H; Dong Q; Luo X; Shi B; Wang H; Gao H; Kong J; Zhang J; Li Z
Cancer Lett; 2014 Jan; 342(1):113-20. PubMed ID: 24007863
[TBL] [Abstract][Full Text] [Related]
49. Identification of an Aurora kinase inhibitor specific for the Aurora B isoform.
Xie H; Lee MH; Zhu F; Reddy K; Peng C; Li Y; Lim DY; Kim DJ; Li X; Kang S; Li H; Ma W; Lubet RA; Ding J; Bode AM; Dong Z
Cancer Res; 2013 Jan; 73(2):716-24. PubMed ID: 23117881
[TBL] [Abstract][Full Text] [Related]
50. The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma.
Lin ZZ; Hsu HC; Hsu CH; Yeh PY; Huang CY; Huang YF; Chen TJ; Kuo SH; Hsu C; Hu FC; Jeng YM; Chung Y; Cheng AL
J Hepatol; 2009 Mar; 50(3):518-27. PubMed ID: 19155085
[TBL] [Abstract][Full Text] [Related]
51. CS2164 exerts an antitumor effect against human Non-Hodgkin's lymphomas in vitro and in vivo.
Deng M; Shi Y; Chen K; Zhao H; Wang Y; Xie S; Zhao J; Luo Y; Fang Z; Fan Y; Xu B
Exp Cell Res; 2018 Aug; 369(2):356-362. PubMed ID: 29864401
[TBL] [Abstract][Full Text] [Related]
52. Quercetin suppresses lung cancer growth by targeting Aurora B kinase.
Xingyu Z; Peijie M; Dan P; Youg W; Daojun W; Xinzheng C; Xijun Z; Yangrong S
Cancer Med; 2016 Nov; 5(11):3156-3165. PubMed ID: 27704720
[TBL] [Abstract][Full Text] [Related]
53. Rapid and cost-effective xenograft hepatocellular carcinoma model in Zebrafish for drug testing.
Tonon F; Zennaro C; Dapas B; Carraro M; Mariotti M; Grassi G
Int J Pharm; 2016 Dec; 515(1-2):583-591. PubMed ID: 27989824
[TBL] [Abstract][Full Text] [Related]
54. In Vitro Characterization of Derrone as an Aurora Kinase Inhibitor.
Hoang NT; Phuong TT; Nguyen TT; Tran YT; Nguyen AT; Nguyen TL; Bui KT
Biol Pharm Bull; 2016 Jun; 39(6):935-45. PubMed ID: 26983907
[TBL] [Abstract][Full Text] [Related]
55. [The anti-tumor activity and molecular mechanisms of an Aurora kinase inhibitor ZLJ213 in suppressing colon cancer growth].
Zhou WQ; Zhang LJ; Yang HZ; Feng ZQ; Li Y
Yao Xue Xue Bao; 2015 Jul; 50(7):854-60. PubMed ID: 26552147
[TBL] [Abstract][Full Text] [Related]
56. AMG 900, a potent inhibitor of aurora kinases causes pharmacodynamic changes in p-Histone H3 immunoreactivity in human tumor xenografts and proliferating mouse tissues.
Juan G; Bush TL; Ma C; Manoukian R; Chung G; Hawkins JM; Zoog S; Kendall R; Radinsky R; Loberg R; Friberg G; Payton M
J Transl Med; 2014 Nov; 12():307. PubMed ID: 25367255
[TBL] [Abstract][Full Text] [Related]
57. Cyclin-Dependent Kinase 9 Inhibition as a Potential Treatment for Hepatocellular Carcinoma.
Shao YY; Hsu HW; Wo RR; Wang HY; Cheng AL; Hsu CH
Oncology; 2022; 100(11):602-611. PubMed ID: 36103810
[TBL] [Abstract][Full Text] [Related]
58. Molecularly Targeted Therapy of Human Hepatocellular Carcinoma Xenografts with Radio-iodinated Anti-VEGFR2 Murine-Human Chimeric Fab.
Huang J; Tang Q; Wang C; Yu H; Feng Z; Zhu J
Sci Rep; 2015 May; 5():10660. PubMed ID: 26021484
[TBL] [Abstract][Full Text] [Related]
59. Osimertinib is a dual inhibitor of hepatocellular carcinoma and angiogenesis in an EGFR-independent manner, and synergizes with venetoclax.
Huang Q; He S; Zhan D
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10727-10735. PubMed ID: 37310474
[TBL] [Abstract][Full Text] [Related]
60. Inhibition of Aurora-B kinase activity confers antitumor efficacy in preclinical mouse models of early and advanced gastrointestinal neoplasia.
Alferez DG; Goodlad RA; Odedra R; Sini P; Crafter C; Ryan AJ; Wedge SR; Wright NA; Anderson E; Wilkinson RW
Int J Oncol; 2012 Oct; 41(4):1475-85. PubMed ID: 22858681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]